Clinical trialNCT04865887RecruitingPhase 2Interventional

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

SponsorGeorgetown UniversityEnrollment35Cervical CancerMetastatic Cervical Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Samir Khleif, MD
Georgetown University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Samir Khleif, MD →
Recruiting
Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
Withdrawn
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
Sharad Ghamande, MD
Recruiting
John Theurer Cancer Center at Hackensack Umc
Hackensack, New Jersey, United States
Donna McNamara, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lenvatinib →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Oct 2022
Primary completion: 31 Jul 2026
Completion: 31 Jul 2026
Last update posted: 7 Oct 2025
Registered enrollment: 35
Registry id: NCT04865887

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.